

- Tosin Oladapo, Health Technology Assessment Analyst
- Present for items 1-9
- Rebecca Brookfield, Health Technology Assessment Analyst
- Present for item 10-16
- Ying-Ying Wang, Health Technology Assessment Analyst
- Present for all items
- Jae Long, Project Manager
- Present for all items
- Ziad Asran, Coordinator
- Present for all items
- Izabela Syrek, Administrator
- Present for all items

External assessment centre (EAC) representatives present:

- Mrs Helen Cole, Head of Service – Clinical Scientist, Newcastle Consortium
- Present for items 1-8
- Dr Iain Willits, Research Scientist, Newcastle Consortium
- Present for items 1-8
- Dr Susan O'Connell, Senior Researcher, Cedar
- Present for items 10-14
- Ms Megan Dale, Senior Researcher, Cedar
- Present for items 10-14

Expert advisers present

- Mr Neil Barber, Consultant Urological Surgeon, Frimley Park Hospital, Frimley Health NHS Foundation Trust
- Present for items 1-8
- Mr Richard Hindley, Consultant Urologist, Basingstoke North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust
- Present for items 1-8
- Dr Allison Farnworth, Senior Research Midwife, Institute of Cellular Medicine at Newcastle University
- Present for items 10-14
- Dr Paul Ayuk, Consultant Obstetrician, Newcastle-upon-Tyne Hospitals NHS Trust
- Present for items 10-14

Non-public present:

- Helen Crosbie, Public Involvement Adviser, Public Involvement Programme, NICE
- Present for all items
- Gareth Murphy, Business Analyst, Resource Impact Assessment Team, NICE
- Present for items 1-9
- Meindert Boysen, Centre Director, Centre for Health Technology Evaluation (HTE), NICE
- Present for items 1-9
- Emilene Coventry, Senior Medical Editor, Publishing Team, NICE
- Present for items 1-9
- Katie Wyart, Medical Technology Implementation Manager, Adoption and Impact Team
- Present for items 1-9
- Ian Mather, Business Analyst, Resource Impact Assessment Team, NICE
- Present for items 10-16
- Tara Chernick, Health Technology Adoption Manager, Adoption and Impact Team
- Present for items 10-16

Introduction to the meeting

1. The chair welcomed all members of the committee and other attendees present to the meeting.

News and announcements

2. The chair offered news and announcements and noted committee members who had given apologies for the meeting.

Minutes of previous meeting

3. The committee agreed the minutes from the 18th October 2019 committee meeting.

MT413 Rezum for treating benign prostatic hyperplasia

Part 1 – Open session

4. The chair welcomed the invited experts, external assessment centre representatives and company representatives from Boston Scientific. The chair then explained the code of conduct to the members of the public observing the meeting.
5. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
 - Mr Neil Barber declared a direct financial interest ahead of the meeting as he received a proctorship fee and travel support from Teleflex / Neotract – providers of competitor products. He also received travel support from Procept-Biorobotics who provide Aquablation therapy of the prostate.
 - It was agreed that his declarations would not prevent Mr Barber from participating in this section of the meeting.
 - Mr Richard Hindley declared a direct financial interest ahead of the meeting as he received a consultancy fee from Boston Scientific for teaching and training. Mr Hindley has been asked to give multiple presentations at meetings. In addition, Mr Hindley's urology group partnership has a number of websites including rezu.co.uk which is used for raising awareness, information and marketing.
 - It was agreed that his declarations would not prevent Mr Hindley from participating in this section of the meeting.

No other interests were declared.

6. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.

7. The topic was introduced by Mr Chris Hudson and Dr David Partridge with Mr Neil Barber and Mr Richard Hindley providing expert advice.
8. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

Part 2 – Closed session

9. The committee then proposed draft recommendations on the technology and these recommendations were reached by consensus.

MT457 Episcissors-60 for guided mediolateral episiotomy

Part 1 – Open session

10. The chair welcomed the invited experts, external assessment centre representatives and company representatives from Medinvent. The chair then explained the code of conduct to the members of the public observing the meeting.
11. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
 - Prof Fiona Denison declared a direct non-financial professional interest ahead of the meeting as she is a member of the intrapartum clinical studies group of the Royal College of Obstetricians and Gynaecologists (RCOG). Since the last committee meeting in September 2019, Dr Ayuk (expert adviser) submitted a draft proposal for trial to evaluate whether episcissors-60 are effective in reducing third / fourth degree tears. Prof Denison has provided comments on this proposal (not involved as a co-applicant) as part of her role as a member of the CSG.
 - It was agreed that her declarations would not prevent Prof Denison from participating in this section of the meeting.
 - Dr Allison Farnworth declared a direct non-financial professional interest ahead of the meeting as she is a co-author on a published paper: “Obstetric anal sphincter injuries (OASIs) before and after the introduction of the Episcissors-60: A multi-centre time series analysis” with Dr Paul Ayuk and Prof Stephen Robson. Dr Farnworth also had time funded by Academic Health Science Network North East and North Cumbria to complete a project exploring implementation of Episcissors-60 in the region (0.2WTE for 12 months).
 - It was agreed that her declarations would not prevent Dr Farnworth from providing expert advice to the committee.
 - Dr Paul Ayuk declared a direct non-financial professional interest ahead of the meeting as he is a lead author of the paper: ‘Obstetric anal sphincter injuries

(OASIs) before and after the introduction of the Episcissors-60: A multi-centre time series analysis.' Revised version submitted for publication.

Dr Ayuk is also at early stages of a proposal for a randomised controlled trial to evaluate the Episcissors-60.

- It was agreed that his declarations would not prevent Dr Ayuk from providing expert advice to the committee.

No other interests were declared.

12. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
13. The topic was introduced by Mr Abdullah Pandor with Dr Allison Farnworth, and Dr Paul Ayuk providing expert advice.
14. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

Part 2 – Closed session

15. The committee then proposed final recommendations on the technology and these recommendations were reached by consensus.

Date of the next meeting

16. The next meeting of the medical technologies advisory committee will be held on Friday 13 December 2019 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.